Samarium

Summary

Samarium (CHEMBL4300244) is a phase-3 clinical-stage small molecule; indicated across 1 condition including metastatic prostate carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4300244
Name	Samarium
Type	Small molecule
Max phase	3

Also known as: Samarium, SM, SAMARIUM

Parent form; salt/anhydrous children: CHEMBL4297426

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
metastatic prostate carcinoma	2	MONDO:0004956	EFO:0000196

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00121095	PHASE1/PHASE2	UNKNOWN	Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer
NCT00126230	PHASE2	TERMINATED	Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer
NCT00374751	PHASE1/PHASE2	COMPLETED	Effect of Samarium on the Relief of Pain Due to Vertebral Metastases
NCT00551525	PHASE2	COMPLETED	Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).